This Tuesday morning, Moderna biotechnology company announced that participants of the “kidCOVE” study have received the first dose of the COVID 19 vaccine.
Children under the age of 12 are under Moderna study to have a vaccine for minors, right now all the vaccines for COVID 19 are for 18 and older individuals.
“We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID and BARDA for their collaboration,” said Stéphane Bancel, chief executive officer of Moderna. “It is humbling to know that 17.8 million adults in the U.S. have received the Moderna COVID-19 vaccine to date. We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population.”
Moderna is testing children from ages 2 to 12 but plans of expanding its study for babies from 6 months old and up. After the second dose of the first age group Moderna will continue with trials for a three dose for children of 12 months.
